Loading
Capmatinib is a targeted pill for the small group of lung cancers driven by a MET exon 14 skipping mutation, found by tumour sequencing.
Capmatinib is an oral MET inhibitor for metastatic non-small cell lung cancer whose tumours carry a MET exon 14 skipping mutation, present in roughly 3 to 4 percent of lung adenocarcinomas. In the GEOMETRY mono-1 trial it produced responses in most untreated patients and in a smaller share of previously treated ones. The FDA granted accelerated approval in 2020. NICE did not complete its appraisal, so it is not routinely funded in England. Peripheral oedema and nausea are the common side effects.
A selective, ATP-competitive inhibitor of the MET receptor kinase; tumours with MET exon 14 skipping mutations keep the receptor switched on, and blocking it shuts down the growth signal. Connects to MET.
1.Capmatinib slips into a pocket on MET.
Sources: NICE TA884. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Adult patients with mNSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Adult patients with mNSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test
Confirmed: the accelerated approval of 2020 converted to traditional approval 2.3 years after it was granted.
| Region | Year | Indication |
|---|---|---|
| US | 2020 | Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
A rare driver with a real drug, and a warning about biomarker thresholds: the same gene, tested the same way, predicts response or does not depending on a copy-number cut-off that has to be measured rather than assumed.
It made MET exon 14 a clinical entity rather than a sequencing curiosity, and identified the patients most likely to be missed: older people whose age would otherwise argue against broad sequencing.
Query for this drug: (TITLE:"Capmatinib" OR ABSTRACT:"Capmatinib" OR TITLE:"Tabrecta" OR ABSTRACT:"Tabrecta" OR TITLE:"INC280" OR ABSTRACT:"INC280") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Capmatinib, not a curated reading list.
Shares MET exon 14 skipping mutation, MET exon 14 skipping mutation, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares GEOMETRY mono-1, MET amplification (gene copy number), MET exon 14 skipping mutation, MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression.
Shares GEOMETRY mono-1, MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.
Shares MET exon 14 skipping mutation, MET amplification (gene copy number), MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, MET.
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Lung cancer (all types).
Shares MET amplification (gene copy number), MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.
Shares Sarcomatoid carcinoma of the lung, MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.
Shares Molecular Profiling of Advanced Soft-tissue Sarcomas, Novartis, Lung cancer (all types), Small-molecule kinase inhibitors.